VC
RVNC

Voss Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Voss Capital’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-45,000
Closed -$730K – 128
2019
Q4 		$730K Buy
+45,000
New +$698K 0.11% 85

Other funds holding RVNC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Voss Capital's RVNC Position: Q1 2020 in Review

Voss Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2020, closing a stake of 45,000 shares — an estimated $730K sold.

Voss Capital first reported a position in RVNC in Q4 2019 and held it in 1 quarter. The position peaked at $730K in Q4 2019. 130 funds tracked by Wall St. Rank hold RVNC as of Q1 2020.

  • Voss Capital reported no remaining Revance Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
  • Voss Capital sold 45,000 Revance Therapeutics, Inc. shares in Q1 2020, an estimated $730K.
  • Voss Capital first reported a position in Revance Therapeutics, Inc. in Q4 2019 and held it in 1 quarter.
  • Voss Capital's Revance Therapeutics, Inc. position peaked at $730K in Q4 2019.
  • 130 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2020.

Based on Voss Capital's 13F filing for Q1 2020, filed 15 May 2020.